Single-arm trial of neoadjuvant ipilimumab plus nivolumab with chemoradiotherapy in patients with resectable and borderline resectable lung cancer: the INCREASE study

Single-arm trial of neoadjuvant ipilimumab plus nivolumab with chemoradiotherapy in patients with resectable and borderline resectable lung cancer: the INCREASE study

Background In non-small cell lung cancer (NSCLC), chemoradiotherapy (CRT) yields pathological complete response (pCR) rates of approximately 30%. We investigated using ipilimumab plus nivolumab (IPI-NIVO) with neoadjuvant CRT in resectable, and borderline resectable NSCLC.Methods This single-arm, ph...

Full description

Saved in:
Bibliographic Details
Main Authors: Tanja D de Gruijl, Lilian J Meijboom, Teodora Radonic, Chris Dickhoff, Idris Bahce, Sayed M S Hashemi, Daniela E Oprea-Lager, Ezgi B Ulas, Suresh Senan, Famke L Schneiders, Joris Veltman, David J Heineman, Anne Vrijmoet, Ilias Houda, Joyce Bakker, Peter van de Ven, Natalja Bouwhuis, Febe van Maldegem, Marieke F Fransen
Format: Article
Language:English
Published: BMJ Publishing Group 2024-09-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/12/9/e009799.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/12/9/e009799.full

Similar Items